[{"id":"b5a9bf94-a0bf-4a0f-b85d-89df1fb88d99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03204188","created_at":"2021-01-18T15:48:00.906Z","updated_at":"2024-07-02T16:35:27.918Z","phase":"Phase 2","brief_title":"Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT03204188","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" TP53 • SF3B1","pipe":" | ","alterations":" TP53 mutation • NOTCH1 mutation • SF3B1 mutation","tags":["TP53 • SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NOTCH1 mutation • SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/22/2017","start_date":" 09/22/2017","primary_txt":" Primary completion: 07/18/2022","primary_completion_date":" 07/18/2022","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-11-28"},{"id":"a15f3c21-a490-40cc-93c8-4d2c83593905","acronym":"","url":"https://clinicaltrials.gov/study/NCT05290337","created_at":"2022-03-22T12:52:47.199Z","updated_at":"2024-07-02T16:36:15.000Z","phase":"Phase 2","brief_title":"ZR-CHOP in DLBCL With Specific Gene Abnormality","source_id_and_acronym":"NCT05290337","lead_sponsor":"Fudan University","biomarkers":" TP53 • MYC • MYD88 • CD79B","pipe":" | ","alterations":" TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation","tags":["TP53 • MYC • MYD88 • CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 01/04/2022","start_date":" 01/04/2022","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2022-03-22"},{"id":"aba33b26-ab98-41c3-96d4-aace62ea6c54","acronym":"","url":"https://clinicaltrials.gov/study/NCT00899366","created_at":"2021-01-18T03:27:26.248Z","updated_at":"2024-07-02T16:36:50.448Z","phase":"","brief_title":"DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00899366","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" NOTCH1","pipe":" | ","alterations":" NOTCH1 mutation","tags":["NOTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 12/28/2006","start_date":" 12/28/2006","primary_txt":" Primary completion: 07/30/2009","primary_completion_date":" 07/30/2009","study_txt":" Completion: 07/30/2009","study_completion_date":" 07/30/2009","last_update_posted":"2020-02-05"}]